Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
75%(6 trials)

Phase Distribution

Ph phase_4
3
38%
Ph phase_2
2
25%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 4Post-market surveillance
3(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 43 (60.0%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_4

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT01298700
completedphase_4

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

NCT01664039
completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT01589510
completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

NCT01489670
completed

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT01568008
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01298700Phase 4

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Completed
NCT01664039Phase 4

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Completed
NCT01589510

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed
NCT01489670

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed
NCT01568008

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed
NCT01464424Phase 4

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Completed
NCT00651859Phase 2

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed
NCT00652496Phase 2

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8